When the FDA Commissioner Tries to Kill a Drug Himself

That's where things get strange. According to Endpoints News, Commissioner Makary was "behind a short-lived request" to reject the application outright, citing agency sources. A rejection at this stage would have taken the form of a Complete Response Letter (CRL), which is the FDA's way of saying "no, try again."

An HHS spokesperson fired back hard, calling the claim "totally false and untrue."

So we have a direct conflict: reporting from agency insiders says the commissioner tried to block the drug, while the government's official position is that it never happened. Someone is not telling the truth.

Why This Matters Way Beyond One Drug

The FDA's credibility rests on a simple bargain with the public. Scientists evaluate the evidence. Politics stays out of it. When a commissioner personally intervenes in a single drug decision, that bargain starts to crack.

Historically, this kind of top-down interference is extraordinarily rare. The closest modern parallel came during COVID, when then-Commissioner Stephen Hahn faced criticism for personally intervening in chloroquine-related decisions under White House pressure. That episode was widely viewed as a cautionary tale, not a precedent to follow.

Under Makary's leadership, the FDA has already drawn scrutiny for rejecting several rare disease therapies, including gene and cell therapies that the agency said lacked sufficient evidence. Makary has publicly defended these decisions as science-driven, insisting that review teams (not political preferences) controlled the outcomes. He's also pushed for more transparency, including publishing rejection letters dating back to 2020.

But transparency and independence are two different things. You can publish every rejection letter in the world; it doesn't matter if the rejection itself was politically motivated.

The DOGE Factor

The backdrop here is important. Makary took over an agency that was already reeling from DOGE-driven mass firings that left hundreds of positions vacant. A strained, understaffed FDA is a vulnerable FDA, one where a strong-willed commissioner might find it easier to exert personal influence over decisions that would normally be insulated from political pressure.

The "heavy workload and limited resources" explanation for missing the PDUFA date reads differently when you know the agency had just lost a chunk of its workforce. Was the delay genuinely about bandwidth, or was it buying time for something else?

The Drug Got Approved Anyway

Whatever happened behind closed doors, sebetralstat was approved on July 3, 2025, about two weeks after the missed deadline. KalVista got its win, and HAE patients got their first oral treatment option.

Analysts stayed largely bullish. Stifel's Paul Matteis maintained a Buy rating with a $39 price target, calling the commissioner's involvement "surprising and unusual." BofA Securities set a $37 target, and the consensus analyst recommendation hovered around Outperform with an average target of $27.25.

What Comes Next

Sebetralstat is now competing in a rapidly expanding HAE market. The 2025 approval wave also brought garadacimab for prevention and donidalorsen as the first RNA-targeting preventive therapy. But sebetralstat occupies a unique lane as the only oral acute treatment, which gives it a clear differentiator for patients who dread needles (which is most people).

The bigger question isn't about KalVista's commercial trajectory. It's about what this episode signals for every other biotech company waiting on an FDA decision. If a commissioner can personally attempt to block a drug that career scientists had no problems with, what's the guardrail? Where's the line between leadership oversight and political interference?

Makary's FDA has positioned itself as a reformer: tougher on evidence, more transparent, willing to say no. Some of that is genuinely good for public health. But reform and interference look very different, even when they wear the same suit. The biotech industry will be watching closely to see which one shows up next.

The Biotech Stock That Crashed, Then Pulled a Houdini

Capricor's Duchenne drug got crushed 9-3 at an FDA advisory committee, and its stock cratered to $4. Then the FDA agreed to review an amended filing, and everything changed overnight. The comeback story Wall Street didn't see coming.